Bexorg, a biotech startup, is pushing the boundaries of neuroscience by extracting human brains shortly after death and connecting them to a life support system known as BrainEX. This innovative approach allows researchers to test experimental drugs, including treatments for Alzheimer's and Parkinson's diseases, on human brain tissue that retains its biological functions despite the absence of consciousness. Brendan Parent, an ethicist at Bexorg, reassures that the extracted brains are devoid of coordinated neural activity, and anesthetics are administered to prevent any potential consciousness. CEO Zvonimir Vrselja emphasizes the advantage of using human brains, which come with decades of environmental exposure and medical history, making them more relevant for drug testing compared to traditional animal models. Bexorg aims to slice and analyze up to 1,600 brains annually, contributing to the growing field of neuroscience research. The ethical implications of this work, particularly regarding the blurred lines between life and death, remain a topic of debate.